TB-500 vs Thymosin beta-4
How they differ
- FDA status. TB-500: Not an FDA-approved drug.1 Thymosin beta-4: No FDA approval reported.2,3
- HHS compounding policy of October 30, 2026. TB-500 is one of the six peptides the policy lists; Thymosin beta-4 is not.4
- FDA compounding safety-risk page. TB-500: listed.3 Thymosin beta-4: not listed.3
- Kinds of studies cited. TB-500: animal and lab studies only. Thymosin beta-4: smaller controlled human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | TB-500 | Thymosin beta-4 |
|---|---|---|
| What it is | A synthetic, N-acetylated peptide matching amino acids 17 to 23 (LKKTETQ) of thymosin beta-4. FDA’s substance registry notes that its identity record does not imply regulatory review or approval.1,5 | Human thymosin beta-4, also recorded as TMSB4 and TB4X in FDA’s substance registry.2 |
| FDA status | Not FDA-approved Not an FDA-approved drug1 Not FDA-approved. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, TB-500 acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,4,6 | Not FDA-approved No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists a thymosin beta-4 fragment, TB-500, among withdrawn nominations, but not thymosin beta-4 itself.2,3 |
| HHS compounding policy, October 30, 2026 | In the policy: one of the six peptides it lists.4 | Not among the six peptides the policy lists.4 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin beta-4 is not among them; TB-500 is a fragment of it.4,6 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, last updated April 22, 2026, lists TB-500 among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.3 | Not listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.3 |
| Kinds of studies cited |
| Smaller controlled human trials
|
| Records collected | 7 ClinicalTrials.gov records and 25 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA briefing document for TB-500 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Thymosin beta-4 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 3Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 5TB-500 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026
- 6Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7ClinicalTrials.gov record NCT07487363 · retained source version 2026-03-23:eb4b60623fcf6b4ae3df79179184b1b2b5a5502180a2163da52ebf8c09c10e1e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 8Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model (2015) · PMID 26056426 ↗
Clinical Ophthalmology · Official source · Source checked November 15, 2026
- 9RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2022) · PMID 36613994 ↗
International Journal of Molecular Sciences · Official source · Source checked November 15, 2026
- 10July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026